Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2022)

Historic Current Deferred Revenue for Inhibikase Therapeutics (IKT) over the last 3 years, with Q3 2022 value amounting to $23683.0.

  • Inhibikase Therapeutics' Current Deferred Revenue changed N/A to $23683.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $23683.0, marking a year-over-year change of. This contributed to the annual value of $2.3 million for FY2020, which is N/A changed from last year.
  • Per Inhibikase Therapeutics' latest filing, its Current Deferred Revenue stood at $23683.0 for Q3 2022.
  • Inhibikase Therapeutics' Current Deferred Revenue's 5-year high stood at $2.3 million during Q4 2020, with a 5-year trough of $23683.0 in Q3 2022.
  • For the 3-year period, Inhibikase Therapeutics' Current Deferred Revenue averaged around $753415.2, with its median value being $142619.0 (2021).
  • The largest annual percentage gain for Inhibikase Therapeutics' Current Deferred Revenue in the last 5 years was 8339.35% (2022), contrasted with its biggest fall of 8339.35% (2022).
  • Quarter analysis of 3 years shows Inhibikase Therapeutics' Current Deferred Revenue stood at $2.3 million in 2020, then tumbled by 93.87% to $142619.0 in 2021, then plummeted by 83.39% to $23683.0 in 2022.
  • Its last three reported values are $23683.0 in Q3 2022, $23684.0 for Q2 2022, and $142619.0 during Q2 2021.